The stabilized bispecific molecule LY3090106 (tibulizumab) potently antagonized both BAFF and IL-17 in cell-based and in vivo mouse models. In cynomolgus monkey, it suppressed B cell development and survival and remained functionally intact in circulation, with a prolonged half-life.

Tibulizumab (ZB-106) is a potential first-in-class, anti-IL-17 and anti-BAFF dual antagonist engineered by the fusion of Taltz® (ixekizumab) and tabalumab. Tibulizumab does not require dual target engagement to achieve biological activity, it is a single agent combination of two independently acting bivalent antagonist moieties.

2025年1月7日 · Zura Bio has launched a Phase 2 trial to evaluate the safety and efficacy of tibulizumab, its experimental dual pathway antibody to treat systemic sclerosis (SSc). The TibuSURE trial is expected to enroll as many as 80 adults with early diffuse cutaneous SSc. They will receive tibulizumab or a placebo for 24 weeks (about six months).

Tibulizumab, an investigational humanized, tetravalent bispecific dual-antagonist antibody, is a fusion of Taltz® (ixekizumab) and tabalumab, engineered to bind to and neutralize both IL-17A and BAFF.

2019年6月10日 · Here, we describe the generation and preclinical characterization of a tetravalent bispecific antibody LY3090106 (tibulizumab) with potent inhibition of both B cell activating factor (BAFF) and interleukin-17A (IL-17).

2024年12月24日 · Zura Bio has initiated the double-blind Phase II TibuSURE trial to assess the humanised tetravalent bispecific dual-antagonist antibody, tibulizumab, in treating systemic sclerosis (SSc), also referred to as scleroderma, in adult patients.

2025年2月7日 · A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis

2023年1月31日 · Tibulizumab (LY 3090106) is a tetravalent bispecific monoclonal antibody targeting human BAFF and IL-17A. Tibulizumab binds to human BAFF and IL-17, but only binds BAFF in mouse. In HT-29 cells, Tibulizumab antagonizes the IL-17-induced secretion of CXCL1 in a concentration-dependent manner.

2019年5月20日 · Tibulizumab is under investigation in clinical trial NCT03736772 (A Study of LY3090106 in Japanese and Caucasian Healthy Participants). The next evolution of DrugBank is here. Designed for scientists, driven by AI, and powered by real-time insights. This is drug intelligence, redefined.

2024年12月27日 · Tibulizumab is an investigational humanized, tetravalent bispecific antibody that combines features of Taltz® and tabalumab. It is engineered to neutralize two key factors involved in inflammation and immune response: IL-17A and BAFF.